R. Tummala - AstraZeneca, Biopharmaceut R&D

基本信息

浏览量：1

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 25 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

A Randomised, Parallel-Group, Double-Blind, Placebo-Controlled Phase 3 Study to Determine the Effectiveness of the Type I Interferon Receptor Antibody, Anifrolumab, in SYstemic Sclerosis: DAISY Study Design and Rationale

D. Khanna,C. P. Denton,S. Assassi,M. Kuwana,Y. Allanore,R. T. Domsic,C. Kleoudis,J. Xu,E. Csomor,C. Seo,M. Albulescu,R. Tummala,H. Al-Mossawi,R. N. Kalyani,F. Del Galdo

CLINICAL AND EXPERIMENTAL RHEUMATOLOGYno. 8 (2024): 1635-1644

引用0浏览0WOS引用

AB0425 WHAT DOES IT MEAN TO BE A DUAL BICLA AND SRI(4) RESPONDER? A POOLED ANALYSIS OF TWO PHASE 3 TRIALS IN PATIENTS WITH SLE

I. N. Bruce, K. Psachoulia, E. Maho,D. Isenberg,R. van Vollenhoven,R. Furie,E. F. Morand,C. Lindholm, M. Hultquist,R. Tummala

ANNALS OF THE RHEUMATIC DISEASES（2022）

引用0浏览0引用

POS0367 IMPROVEMENT OF INDIVIDUAL MUCOCUTANEOUS MANIFESTATIONS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS TREATED WITH ANIFROLUMAB

V. Werth, J. Wissmar, A. Strombeck,R. Tummala,C. Kleoudis,M. Albulescu

Annals of the Rheumatic Diseasesno. Suppl 1 (2022): 436.2-437

引用1浏览0引用

POS0733 DISCORDANCE BETWEEN PATIENT GLOBAL ASSESSMENT AND PHYSICIAN GLOBAL ASSESSMENT OF DISEASE ACTIVITY IN THE MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS PROSPECTIVE OBSERVATIONAL COHORT STUDY (SPOCS)

L. Arnaud,R. Furie,E. F. Morand,C. Peschken,M. Aringer,E. Rapsomaniki,J. Hedberg,J. Knagenhjelm,C. Seo,T. Grunfeld Een,B. Desta, A. Sorrentino,R. Tummala,H. Stirnadel-Farrant

ANNALS OF THE RHEUMATIC DISEASES（2022）

引用0浏览0引用

OP0282 IMPACT OF ANIFROLUMAB ON NEUROPSYCHIATRIC MANIFESTATIONS OF DEPRESSION AND SUICIDALITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

S. Manzi,C. Lindholm, I. Hupka,L. J. Zhang,M. Shroff,G. Abreu,S. Werther,R. Tummala

Annals of the Rheumatic Diseasesno. Suppl 1 (2022): 187-188

引用0浏览0引用

POS0739 THE RENAL ACTIVITY INDEX FOR LUPUS (RAIL) DIFFERENTIATES ACTIVE AND INACTIVE NEPHRITIS IN ADULT PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

E. Cody,H. Brunner,B. Huang,T. Qiu,P. Devarajan, M. Ramaswamy,D. Sinibaldi,P. Z. Brohawn,J. Knagenhjelm, F. Jones,R. Tummala,C. Lindholm,W. White

ANNALS OF THE RHEUMATIC DISEASES（2022）

引用0浏览0引用

IMPACT OF ANIFROLUMAB ON NEUROPSYCHIATRIC MANIFESTATIONS OF DEPRESSION AND SUICIDALITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

S. Manzi,C. Lindholm, I. Hupka,L. J. Zhang,M. Shroff,G. Abreu,S. Werther,R. Tummala

ANNALS OF THE RHEUMATIC DISEASES（2022）

引用0浏览0引用

POS0708 EVALUATING THE HYPERSENSITIVITY PROFILE OF ANIFROLUMAB AND THE NEED FOR PREINFUSION PROPHYLACTIC TREATMENT IN PATIENTS WITH SLE

K. C. Kalunian,Y. Tanaka, I. Hupka,L. J. Zhang,M. Shroff,S. Werther,G. Abreu,C. Lindholm,R. Tummala

Annals of the Rheumatic Diseases（2022）

引用0浏览0引用

POS0731 ASSOCIATION OF PATIENT-REPORTED OUTCOMES WITH TYPE I INTERFERON GENE SIGNATURE FROM THE INTERNATIONAL SYSTEMIC LUPUS ERYTHEMATOSUS PROSPECTIVE OBSERVATIONAL COHORT STUDY (SPOCS)

M. Aringer,L. Arnaud,C. Peschken,R. Furie,E. F. Morand,C. Seo,E. Rapsomaniki,J. Hedberg,J. Knagenhjelm,T. Grunfeld Een,B. Desta,R. Tummala, A. Sorrentino,H. Stirnadel-Farrant

Annals of the Rheumatic Diseases（2022）

引用0浏览0引用

POS0709 SUSTAINED BICLA AND BILAG ORGAN DOMAIN RESPONSES IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) RECEIVING ANIFROLUMAB IN TWO PHASE 3 TRIALS

R. Van Vollenhoven,R. Furie,E. F. Morand,R. Tummala, E. Maho,C. Lindholm

Annals of the Rheumatic Diseases（2022）

引用1浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn